Imugene Extends Share Purchase Plan Deadline to Enhance Shareholder Participation

Imugene ( (AU:IMU) ) just unveiled an update.

Imugene Limited has announced an extension to the closing date of its $15 million share purchase plan (SPP) to 25 August 2025, allowing shareholders additional time to consider the offer. This decision follows feedback from shareholders and is part of the company’s broader fundraising efforts, which include a recently completed $22.5 million placement. The extension aims to ensure greater shareholder participation and engagement, potentially strengthening Imugene’s financial position and supporting its ongoing immunotherapy development initiatives.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene is a clinical stage immuno-oncology company focused on developing novel immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company utilizes unique platform technologies to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than those of synthetically manufactured monoclonal antibodies and other immunotherapies. Their pipeline includes an off-the-shelf cell therapy CAR T drug, azer-cel.

YTD Price Performance: -78.93%

Average Trading Volume: 1,428,948

Technical Sentiment Signal: Sell

Current Market Cap: A$76.45M

For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.